NO20015712L - Hydrokloridet av sammensmeltede heterosykliske forbindelser - Google Patents

Hydrokloridet av sammensmeltede heterosykliske forbindelser

Info

Publication number
NO20015712L
NO20015712L NO20015712A NO20015712A NO20015712L NO 20015712 L NO20015712 L NO 20015712L NO 20015712 A NO20015712 A NO 20015712A NO 20015712 A NO20015712 A NO 20015712A NO 20015712 L NO20015712 L NO 20015712L
Authority
NO
Norway
Prior art keywords
hydrochloride
heterocyclic compounds
fused heterocyclic
benzylüthiazolid
ylmethoxy
Prior art date
Application number
NO20015712A
Other languages
English (en)
Other versions
NO321578B1 (no
NO20015712D0 (no
Inventor
Takashi Fujita
Toshihiko Fujiwara
Takashi Izumi
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15340495&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20015712(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20015712D0 publication Critical patent/NO20015712D0/no
Publication of NO20015712L publication Critical patent/NO20015712L/no
Publication of NO321578B1 publication Critical patent/NO321578B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20015712A 1999-05-24 2001-11-23 Medikament inneholdende forbindelsen 5-[4-(6-metoksy-1-metyl-1H-benzimidazol-2-ylmetoksy)benzyl]-2,4-dionhydroklorid eller et solvat derav som en aktiv ingrediens derav og anvendelse av det samme for fremstilling av et medikament for forbedring av insulinresistens, for profylakse eller behandling av hyperglykemi, profylakse eller behandling av diabetiske komplikasjoner og profylakse og eller behandling av svekket glukosetoleranse. NO321578B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP14351399 1999-05-24
PCT/JP2000/003325 WO2000071540A1 (en) 1999-05-24 2000-05-24 Hydrochloride of fused-heterocycle compound

Publications (3)

Publication Number Publication Date
NO20015712D0 NO20015712D0 (no) 2001-11-23
NO20015712L true NO20015712L (no) 2001-12-20
NO321578B1 NO321578B1 (no) 2006-06-06

Family

ID=15340495

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015712A NO321578B1 (no) 1999-05-24 2001-11-23 Medikament inneholdende forbindelsen 5-[4-(6-metoksy-1-metyl-1H-benzimidazol-2-ylmetoksy)benzyl]-2,4-dionhydroklorid eller et solvat derav som en aktiv ingrediens derav og anvendelse av det samme for fremstilling av et medikament for forbedring av insulinresistens, for profylakse eller behandling av hyperglykemi, profylakse eller behandling av diabetiske komplikasjoner og profylakse og eller behandling av svekket glukosetoleranse.

Country Status (25)

Country Link
US (1) US6706746B2 (no)
EP (1) EP1180519B1 (no)
KR (2) KR100748053B1 (no)
CN (1) CN1156473C (no)
AT (1) ATE294799T1 (no)
AU (1) AU763731B2 (no)
BR (1) BR0010914A (no)
CA (1) CA2375017C (no)
CZ (1) CZ297927B6 (no)
DE (1) DE60019919T2 (no)
DK (1) DK1180519T3 (no)
ES (1) ES2240099T3 (no)
HK (1) HK1042087B (no)
HU (1) HU229340B1 (no)
IL (1) IL146568A0 (no)
MX (1) MXPA01012044A (no)
NO (1) NO321578B1 (no)
NZ (1) NZ515570A (no)
PL (1) PL209389B1 (no)
PT (1) PT1180519E (no)
RU (1) RU2214410C2 (no)
TR (1) TR200103353T2 (no)
TW (1) TWI284533B (no)
WO (1) WO2000071540A1 (no)
ZA (1) ZA200109576B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
ATE341343T1 (de) 2000-12-26 2006-10-15 Sankyo Co Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
US6756399B2 (en) * 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
WO2003082865A1 (en) * 2002-04-01 2003-10-09 Sankyo Company, Limited Medicinal antitumor composition
TW200408628A (en) * 2002-08-02 2004-06-01 Sankyo Co Resorcinol and its derivatives
US7781464B2 (en) * 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US6794401B2 (en) * 2003-01-17 2004-09-21 Bexel Pharmaceuticals, Inc. Amino acid phenoxy ethers
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
JPWO2004106542A1 (ja) 2003-05-29 2006-07-20 三共株式会社 インスリン抵抗性改善剤及びそのスクリーニング方法
US7087576B2 (en) * 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
CN1870997B (zh) * 2003-10-24 2011-05-04 参天制药株式会社 角膜结膜病变的治疗剂
EP1566202A1 (en) * 2004-02-23 2005-08-24 Sahltech I Göteborg AB Use of resistin antagonists in the treatment of rheumatoid arthritis
EP1731170A1 (en) * 2004-03-29 2006-12-13 Sankyo Company, Limited Therapeutic agent for diabetes containing insulin resistance improving agent
TW200608967A (en) 2004-07-29 2006-03-16 Sankyo Co Pharmaceutical compositions containing with diabetic agent
WO2006064744A1 (ja) * 2004-12-13 2006-06-22 Daiichi Sankyo Company, Limited 糖尿病の治療のための医薬組成物
BRPI0519015A2 (pt) * 2004-12-15 2008-12-23 Daiichi Sankyo Co Ltd composiÇço farmacÊutica, agente profilÁtico ou agente terapÊutico, agentes para melhorar a funÇço das cÉlulas b no pÂncreas, e para a reduÇço da razço da hemoglobina glicosilada, e, usos da 5-[4-(6-metàxi-1-metil-1h-benzimidazol-2-ilmetàxi)benzi l] tiazolidina-2,4-diona ou de um sal farmacologicamente aceitÁvel da mesma e de um inibidor de fbpase, e do 2-amino-5-isobutil-4-[2-[5-(n,n'-bis((s)-1etoxicarbonil)eti l) fosfonamido] furanil} tiazol ou de um sal farmacologicamente aceitÁvel do mesmo
TW200637856A (en) * 2005-01-24 2006-11-01 Sankyo Co Process for producing thiazolidinedion compound and intermediate thereof
EP1889618A4 (en) * 2005-05-27 2010-11-24 Daiichi Sankyo Co Ltd Combined drug for treating diabetes
EP1902713A4 (en) * 2005-07-08 2009-05-13 Daiichi Sankyo Co Ltd A PHIAZEUTIC COMPOSITION CONTAINING A THIAZOLIDINDEIDE COMPOUND
TW200738266A (en) * 2005-09-29 2007-10-16 Sankyo Co Pharmaceutical agent containing insulin resistance improving agent
EP1964575B1 (en) 2005-11-28 2015-09-23 Senju Pharmaceutical Co., Ltd. Pharmaceutical comprising ppar agonist
TW200838512A (en) * 2007-02-08 2008-10-01 Daiichi Sankyo Co Ltd Crystalline forms of a thiazolidinedione compound and manufacturing methods thereof
AU2008239179B2 (en) * 2007-04-05 2011-02-24 Daiichi Sankyo Company, Limited Fused bicyclic heteroaryl derivatives
US8802705B2 (en) 2007-05-21 2014-08-12 Senju Pharmaceutical Co., Ltd. Pharmaceutical containing PPAR delta agonist
US8722710B2 (en) 2007-09-26 2014-05-13 Deuterx, Llc Deuterium-enriched pioglitazone
KR20110123253A (ko) 2009-03-05 2011-11-14 다이이찌 산쿄 가부시키가이샤 피리딘 유도체
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
US10188639B2 (en) 2014-01-15 2019-01-29 Deuterx, Llc Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
US11767317B1 (en) 2020-06-30 2023-09-26 Poxel Sa Methods of synthesizing enantiopure deuterium-enriched pioglitazone
US11319313B2 (en) 2020-06-30 2022-05-03 Poxel Sa Crystalline forms of deuterium-enriched pioglitazone

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143930A (en) * 1990-02-07 1992-09-01 Sankyo Company, Limited Thiazolidine derivatives with anti-diabetic activity, their preparation and their use
CZ293016B6 (cs) * 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
US5798375A (en) 1995-07-03 1998-08-25 Sankyo Company, Limited Treatment of arteriosclerosis and xanthoma
TWI284533B (en) * 1999-05-24 2007-08-01 Sankyo Co Pharmaceutical composition for treating hyperglycemia, impaired glucose tolerance, diabetes complications and for improving insulin resistant
HUP0202340A3 (en) * 1999-07-19 2006-03-28 Sankyo Company Ltd Chuo Ku Pharmaceutical compositions containing condensed heterocyclic compounds as active ingredient and their use

Also Published As

Publication number Publication date
PL351650A1 (en) 2003-05-19
EP1180519A1 (en) 2002-02-20
KR20010113972A (ko) 2001-12-28
KR100783348B1 (ko) 2007-12-07
DK1180519T3 (da) 2005-06-13
US6706746B2 (en) 2004-03-16
KR20070034112A (ko) 2007-03-27
HUP0201334A2 (en) 2002-10-28
NZ515570A (en) 2003-11-28
HU229340B1 (en) 2013-11-28
TWI284533B (en) 2007-08-01
DE60019919T2 (de) 2006-02-16
ES2240099T3 (es) 2005-10-16
TR200103353T2 (tr) 2002-04-22
CN1364168A (zh) 2002-08-14
CA2375017A1 (en) 2000-11-30
IL146568A0 (en) 2002-07-25
NO321578B1 (no) 2006-06-06
EP1180519A4 (en) 2002-07-10
BR0010914A (pt) 2002-02-19
EP1180519B1 (en) 2005-05-04
RU2214410C2 (ru) 2003-10-20
HK1042087B (en) 2005-09-09
CN1156473C (zh) 2004-07-07
WO2000071540A1 (en) 2000-11-30
PT1180519E (pt) 2005-06-30
MXPA01012044A (es) 2002-05-06
HUP0201334A3 (en) 2002-11-28
KR100748053B1 (ko) 2007-08-09
CZ20014182A3 (cs) 2002-04-17
HK1042087A1 (en) 2002-08-02
PL209389B1 (pl) 2011-08-31
ATE294799T1 (de) 2005-05-15
US20020111373A1 (en) 2002-08-15
DE60019919D1 (de) 2005-06-09
AU4948700A (en) 2000-12-12
AU763731B2 (en) 2003-07-31
NO20015712D0 (no) 2001-11-23
CZ297927B6 (cs) 2007-05-02
ZA200109576B (en) 2003-02-20
CA2375017C (en) 2009-05-19

Similar Documents

Publication Publication Date Title
NO20015712D0 (no) Hydrokloridet av sammensmeltede heterosykliske forbindelser
EA200200661A1 (ru) 3-аминохиназолин-2,4-дионовые антибактериальные агенты
DE69803907D1 (de) Fungizide 2-Methoxybenzophenone
TR199902400T2 (xx) Fungusit etkinlik g�steren terkiplerin birle�imleri.
ATE315560T1 (de) Polyhydroxylierte heterocyclische derivate als antikoagulanten
ES2182234T3 (es) Inhibidores de metaloproteasa.
IT1317865B1 (it) Combinazione di stabilizzanti per il procedimento di stampaggio arotazione.
EA200200699A1 (ru) Оксазолидиноны, обладающие сульфоксиминовой функциональностью
ATE183189T1 (de) Antifungale sordaridinderivate
BR9611811A (pt) Pesticidas
IT1317751B1 (it) Poliolefine di metalloceni stabilizzate.
EP1357124A4 (en) HETEROCYCLIC COMPOUNDS AND COMPOSITIONS IMPROVING CEREBRAL FUNCTIONS CONTAINING THESE AS ACTIVE INGREDIENTS
BR9914736A (pt) Compostos de 3-(fenil substituìdo)-5-tienil-1,2,4-triazol com atividade contra mosca branca
ATE250021T1 (de) Hydroxycyclopentanone
NO974588L (no) Triazol-antifungalt middel
EP0773214A4 (en) TRIFLUOROMETHYLQUINOLEINECARBOXYLIC ACID
ATE299869T1 (de) (-)-enantiomeres des 2-(2-(1-chlor-cyclopropyl)-3-(2-chlorphenyl) -2-hydroxypropyl)-2,4-dihydro-(1, 2,4)-triazol-3-thions
DE60214719D1 (de) 8-CHLOR-11-(4-ETHYL-PIPERAZINYL)-DIBENZOiB,Föi1,4öOXAZEPIN ALS ATYPISCH ANTIPSYCHOTISCHER WIRKSTOFF MIT GERINGER AFFINITÄT FÜR DEN D2 REZEPTOR
DE69937771D1 (de) 1-Aryl-4-cycloalk(en)ylpyrazole als antiparasitäre Mittel
EA200200160A1 (ru) Аналоги псевдомицина с n-ацильной боковой цепью
DE60039695D1 (de) Antifucoidan antikörper
BR9902348A (pt) Derivados de piridazinona
ES2195309T3 (es) Derivados de tetrahidrofurano.
EP1211245A4 (en) AGENTS FOR CONTROLLING ANIMAL DISEASES CAUSED BY PESTS
ITMI20010283V0 (it) Porta ad impacchettamento rapido, ad elevata semplicita' di assemblaggio.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees